Replimune Group, Inc.

Equities

REPL

US76029N1063

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-08 pm EDT			5-day change	1st Jan Change
8.44 ^USD	+4.07%		-9.83%	+0.12%

Jun. 24	Replimune Group, Inc.(NasdaqGS:REPL) dropped from S&P Biotechnology Select Industry Index	CI
Jun. 13	Replimune Group Signs $100 Million PIPE Deal with Institutional Investors	MT

Replimune Group, Inc. Announces Departure of Dr. Otello Stampacchia from its Board of Directors

January 31, 2022 at 04:01 pm EST

Replimune Group Inc. announced Otello Stampacchia, Ph.D., of Omega Funds, has resigned from the company's Board of Directors. Dr. Stampacchia joined the Replimune Board in 2015, concurrent with Omega co-leading Replimune's seed financing. Dr. Stampacchia has resigned to focus his efforts on his growing commitments at Omega and its many portfolio companies.

Latest news about Replimune Group, Inc.

Replimune Group, Inc.(NasdaqGS:REPL) dropped from S&P Biotechnology Select Industry Index	Jun. 23	CI
Replimune Group Signs $100 Million PIPE Deal with Institutional Investors	Jun. 13	MT
Replimune Group, Inc. announced that it expects to receive $100.000032 million in funding	Jun. 11	CI
Transcript : Replimune Group, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 02:00 PM	Jun. 11
HC Wainwright Adjusts Price Target on Replimune to $17 From $12, Maintains Buy Rating	Jun. 07	MT
Sector Update: Health Care Stocks Higher in Late Afternoon Trading	Jun. 06	MT
Sector Update: Health Care	Jun. 06	MT
Replimune Shares Rise as Study Data on Melanoma Treatment Improves	Jun. 06	MT
Transcript : Replimune Group, Inc. - Special Call	Jun. 06
Replimune Group, Inc. Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of Rp1 Plus Nivolumab in Anti-Pd1 Failed Melanoma	Jun. 06	CI
Replimune Presents Positive Data from Rp1 and Rp2 Clinical Programs At the 2024 American Society of Clinical Oncology Annual Meeting	Jun. 03	CI
Replimune Group, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024	May. 16	CI
Replimune Group Provides Interim Results for Skin Cancer Therapy	Apr. 08	MT
Replimune Group, Inc. Announces Management Changes	Mar. 26	CI
Replimune Group, Inc. Announces CEO Changes, Effective April 1, 2024	Mar. 26	CI
Transcript : Replimune Group, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 10:45 AM	Mar. 14
Wedbush Raises Replimune Group's PT to $16 From $14 After Adjusting Financing Assumptions, Keeps Outperform Rating	Feb. 09	MT
Replimune Group, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 08	CI
Transcript : Replimune Group, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 11:15 AM	Jan. 08
Wedbush Cuts Replimune Group's PT to $14 From $52 After Narrow Complete Response Rate Miss in Phase 2 Trial of Skin Cancer Treatment Candidate; Keeps Outperform Rating	Dec. 06	MT
Barclays Lowers Price Target on Replimune Group to $13 From $50, Keeps Overweight Rating	Dec. 06	MT
Sector Update: Health Care Stocks Ease Late Afternoon	Dec. 05	MT
Sector Update: Health Care	Dec. 05	MT
Replimune Group Shares Slide as Trial of Skin Cancer Treatment Candidate Failed to Meet Primary Endpoints	Dec. 05	MT
Transcript : Replimune Group, Inc. - Special Call	Dec. 05

Chart Replimune Group, Inc.

Duration

Period

More charts

Company Profile

Replimune Group, Inc. a clinical-stage biotechnology company engaged in the development of a novel class of oncolytic immunotherapies. The Companyâs proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. RP1 (vusolimogene oderparepvec) is its lead product candidate and is based on a proprietary strain of herpes simplex virus engineered and genetically armed with a fusogenic protein (GALV-GP R-) and GM-CSF intended to maximize tumor killing potency, the immunogenicity of tumor cell death, and the activation of a systemic anti-tumor immune response. It is also developing additional product candidates, RP2 and RP3, to enhance anti-tumor immune responses and are intended to address additional tumor types, including traditionally less immune responsive tumor types. RP2 additionally expresses an anti-CTLA-4 antibody-like molecule, as well as GALV-GP R- and GM-CSF.

Sector

Biotechnology & Medical Research

Calendar

2024-07-31 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.44 USD

Average target price

14.33 USD

Spread / Average Target

+69.83%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
REPLIMUNE GROUP, INC.	+0.12%	518M
MODERNA, INC.	+17.09%	44.63B
LONZA GROUP AG	+42.78%	40.46B
IQVIA HOLDINGS INC.	-9.70%	38.07B
ALNYLAM PHARMACEUTICALS, INC.	+33.28%	32.27B
CELLTRION, INC.	-8.98%	27.3B
ICON PUBLIC LIMITED COMPANY	+13.37%	26.53B
UNITED THERAPEUTICS CORPORATION	+44.11%	14.06B
MEDPACE HOLDINGS, INC.	+32.33%	12.54B
BIO-TECHNE CORPORATION	-7.26%	11.28B

Other Biotechnology & Medical Research